3 311

Cited 8 times in

Effect of Combined Bevacizumab and Temozolomide Treatment on Intramedullary Spinal Cord Tumor

 So-Jung Gwak  ;  Sung Su An  ;  Moon Sul Yang  ;  Eunhae Joe  ;  Dong-Hyun Kim  ;  Do Heum Yoon  ;  Keung Nyun Kim  ;  Yoon Ha 
 SPINE, Vol.39(2) : 65-73, 2014 
Journal Title
Issue Date
Animals ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage* ; Bevacizumab ; Cell Line, Tumor ; Dacarbazine/administration & dosage ; Dacarbazine/analogs & derivatives ; Male ; Rats ; Rats, Sprague-Dawley ; Spinal Cord Neoplasms/drug therapy* ; Spinal Cord Neoplasms/pathology* ; Treatment Outcome
bevacizumab ; temozolomide ; intramedullary spinal cord tumor
STUDY DESIGN: C6 glioma cells and an intramedullary spinal cord tumor model were used to evaluate the effect of bevacizumab (Avastin) or temozolomide (TMZ). OBJECTIVE: In this study, we hypothesized that treatment with bevacizumab accelerates the therapeutic effect of TMZ on intramedullary gliomas in an animal model. SUMMARY OF BACKGROUND DATA: Recently therapies for the management of intramedullary malignant gliomas include surgery, chemotherapy, and radiotherapy. Concurrent or adjuvant TMZ has been considered an emerging new treatment for intramedullary malignant gliomas; however, high-dose application of TMZ has limitation of side effect. METHODS: C6 glioma cells were injected into the T5 level of the spinal cord, and TMZ and bevacizumab were administered 5 days after C6 inoculation (n = 7 for each group). Tumor size was analyzed using histology and magnetic resonance imaging at 13 days after tumor inoculation. RESULTS: Histological analyses and magnetic resonance imaging findings showed that combined treatment with TMZ and bevacizumab reduced tumor mass. The tumor volume of control group was 2.8-fold higher than combined therapy (P < 0.05). Neurological outcomes demonstrated that combined therapy improved hind limb function more than TMZ-alone group or control group (P < 0.05). CONCLUSION: This study shows that bevacizumab could be useful in combination with TMZ to increase the therapeutic benefits of TMZ for intramedullary spinal cord tumors. LEVEL OF EVIDENCE: N/A.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
Yonsei Authors
Gwak, So Jung(곽소정)
Kim, Keung Nyun(김긍년)
An, Sung Su(안성수)
Yang, Moon Sool(양문술)
Yoon, Do Heum(윤도흠) ORCID logo https://orcid.org/0000-0003-1452-5724
Ha, Yoon(하윤)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.